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Background: There is increasing evidence demonstrating the co-occurrence of primary 
dysmenorrhea (PD), premenstrual syndrome (PMS), and irritable bowel syndrome (IBS) in 
women. This study aimed to investigate whether women who have symptoms of IBS in 
addition to PD and PMS also report more severe or frequent menstruation-associated 
symptoms and psychological complications compared to women with PD and PMS alone. 
Methods: The study group included 182 female University students aged 18-25 years. IBS 
was diagnosed using the Rome III criteria. The severity of PMS and PD was determined 
using a 10-point visual analog scale and PSST (Premenstrual Syndrome Screening Tool), 
respectively. Neuropsychological function including cognitive function, depression score, 
anxiety score, stress, insomnia, daytime sleepiness, quality of life and personality were 
assessed using standard questionnaires. 
Results: Of the 182 young females, 31(17.0%) had IBS. Average days of bleeding during the 
menstrual cycle and mean pain severity on the PSST scale were significantly greater in the 
group with IBS compared to the non-IBS group (P<0.01). The non-IBS individuals scored 
more favorably than the women with IBS with respect to severity of depression, insomnia, 
daytime sleepiness (P<0.05). The PSST scores were significantly correlated with scores for 
depression (r=0.29; p<0.001), anxiety (r=0.28; p<0.001), stress (r=0.32; p<0.001), insomnia 
(r=0.34; p<0.001) and daytime sleepiness (r=0.31; p<0.001); while they were negatively 
correlated with cognitive abilities (r=-0.20; p=0.006) and quality of life (r=-0.42; p<0.001). 
Linear regression analysis showed that the PSST scores were possibly significant factors in 
determining the scores for depression, anxiety, stress, quality of life, insomnia and daytime 
sleepiness (P<0.05). 
Conclusion: IBS is related to psychological comorbidities, in particular depression, sleep 
problems and menstrual-associated disorders. IBS may exacerbate the features of PMS which 
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1. Introduction 
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder 
characterized by abdominal pain or discomfort together with alteration of bowel habits in the 
lack of structural abnormalities [1]. Epidemiologic studies have reported the prevalence of 
IBS is approaching 11% globally [2] and 1.1% to 25% in Iranian populations [3, 4]. 
The pathogenesis of IBS involves the interactions of several factors i.e. abnormal 
gastrointestinal motility, visceral hypersensitivity, and elevated pain perception [5, 6], dietary 
intolerance [7], disturbance of brain–gut axis function [8, 9], chronic inflammation, changing 
gut immune induction [10], intestinal permeability and reorganization of microbiota [11], 
psychosocial stressors and psychiatric comorbidities [12]. Patients with IBS endure high 
levels of psychological distress; these have been reported to be at intermediate levels between 
psychiatric cases and healthy individuals[13]. Psychiatric comorbidities such as depression 
may also be involved in the negative effect of IBS on the quality of life [14]. The large 
intestine is partly regulated via the autonomic nervous system and reacts to stress. Manifested 
by increments of the sensation together motility of the large intestine [15].  
Sex hormones may also contribute to the etiology of IBS. This is supported by the fact that 
IBS is more prevalent in women compared to men [16]. Menarche defines the beginning of 
menstruation and it is one of the most impactful events in a women's life; women of 
reproductive age are often negatively affected by symptoms corresponding to menstrual 
dysfunction such as premenstrual syndrome (PMS) and primary dysmenorrhea (PD) [17]. 
PD can be defined as a presence of spasmodic-like pain in the lower abdomen, without any 
pelvic pathology, at shortly before or the onset of menstruation, which occur in up to 90% of 
woman [18]. Some days prior to menstruation, prostaglandins act on the uterine muscle 
where they increase the speed of onset of menstruation and smooth muscle contraction [19]. 
Premenstrual syndrome (PMS) is a set of physiological and affective symptoms happening 
within the one week prior to menses, after which there is an attenuation over a few days 
following the onset of menstrual bleeding, or shortly thereafter [20]. The frequency and 
intensity of PMS symptoms differ considerably between women [21, 22]. Between 70-90% 
of women experience one or more signs of physical discomfort or psychological symptoms 
during the luteal phase of their menstrual cycle [23, 24]. 
The presentation of IBS symptoms and the associated changes in bowel habit, may vary over 
the phases of the menstrual cycle, indicating a potential effect of gonadal hormones on 
gastrointestinal symptoms [23, 25]. We have previously reported that among 448 adolescent 
girls, the prevalence of IBS was significantly higher in the individuals with PD (19.9%), 
cases with PMS (13.6%), and individuals with both PMS and PD (17.4%) compared to health 
controls (8.1%) [26]. In spite of the documented co-occurrence of PD and PMS with IBS, 
these conditions have generally been explored as separate entities and so, there is scarce 
existing information on their combined impact. It remains unknown whether women with 
concurrent PMS and PD who report IBS have elevated levels of physiological and 
psychological distress. This study aimed to investigate that women who report IBS in 
addition to PD and PMS will also report more severe or frequent menstruation-associated 
symptoms and psychological complications compared to women with PD and PMS alone.  
2. Material and Methods 
2.1.Study design and participants 
This study was performed on female university students suffering from PMS and PD during 
November-December 2019 from 5 universities in Birjand city, Khorasan Province, Iran. The 
sample size was determined to achieve 80% power and α’ = 0.05 according to a previous 
study [26] and it was determined that 173 cases would be needed for sufficient power. The 
inclusion criteria of study were: a natural menstrual cycle, being single civil status 
(unmarried), having both PMS and PD which had started within 2 years of menarche. The 
exclusion criteria were any acute or chronic systemic diseases; and any history of pelvic or 
abdominal surgery. We also excluded girls with any endocrinopathy, endometriosis and/or 
adenomyosis, fibroids, secondary dysmenorrhea and other gynecological complications 
which were diagnosed by expert gynecologist or self-reported. Girls, who were using any 
medication and hormone therapy over the past year, were also elided. The study was 
approved by the Ethics Committee of Birjand University of Medical Sciences (BUMS) and 
informed consent was obtained from each participants. 
2.2.Diagnosis of IBS, premenstrual syndrome and dysmenorrhea 
2.2.1. Dysmenorrhea 
These following criteria were used to define PD: pain beginning within 6-12 hours of 
menstruation, lower abdominal pain related with onset of menarche and extended over 8-72 
hour, as well as low back pain or anterior thigh during menses [27]. 
The dysmenorrheal pain severity was measured in each participants using a visual analogue 
scale (VAS), with scores from 1-10. Pain was defined as "mild" when a female rated 1-
3,"moderate" when rated 4-5, "severe" when rated 6-7, or "extreme severe" with a score of 8-
10 [28]. 
2.2.2. Premenstrual syndrome 
PMS was determined using the PSST (Premenstrual Syndrome Screening Tool) questionnaire 
[29], which consists of 19 items in three section (physical, behavioral and psychological 
symptoms) in the 5 days prior to menstruation of the previous 3 months. The severity of each 
symptom was graded from 0 to 3 based on 4-options Likert scale (0: none, 3: severe), 
covering the lowest and highest range of 0 and 57. The individuals who obtained scores 
greater than 20 were enrolled to the present study. This scale was validated in Iran. Notably, 
the reliability, internal consistency, and the validity of the questionnaire for Iranian 
population were 0.9, 0.8, and 0.7, respectively[30]. 
2.2.3. Menstrual pattern  
 
Menstrual patterns of participants were evaluated by standard questionnaires which included 
the menarcheal age, menstrual cycle length, duration and amount of flow[31]. 
2.2.4. IBS 
This part of questionnaire consisted of questions about various gastrointestinal disorders, 
described on the basis of Rome III criteria translated into Persian. IBS was defined as 
repeated abdominal pain/discomfort at least 3 days per month in the last 2 months 
accompanied with 2>of the following criteria:1) Relief with defecation, 2) the beginning 
related with an alteration in frequency and 3) alteration in appearance of stool [1]. IBS and 
four subtypes including constipation-predominant (IBS-C), diarrhea predominant (IBS-D), 
mixed bowel habit (IBS-M), and unclassified IBS, were diagnosed based on the Rome III 
criteria and explanation of recent symptoms. The validity and reliability of this questionnaire 
in Iranian individuals has been reported previously [32]. 
 
2.3.Anthropometric measurements and blood collection 
Demographic information was gathered by face-to-face interview. Anthropometric indices 
(waist and hip circumference, weight, height) and cardiac measurements were assessed using 
validated instruments and standard procedure in our health centers by expert paramedic. 
Body mass index (BMI) was also calculated by using this formula: weight (kg)/height (m2). 
Five mL EDTA blood samples were collected from each participant in morning and 
hematological indices immediately were measured by using the SysmexK-800. 
2.4.Neuropsychological assessment 
Cognitive abilities were evaluated using the Cognitive Abilities Questionnaire (CAQ). The 
CAQ consists of 30 questions, each of which is scored on 1–5 and thus a total score obtaining 
from 30 to 150. Higher scores indicated superior cognition performances [33]. The CAQ 
measures memory, inhibitory control and selective attention, decision making, planning, 
sustained attention, social cognition and cognitive flexibility [34]. 
Depression Anxiety and Stress Scale (DASS-21) [35] is a commonly used, and has been 
well-validated for measuring of negative emotions. This 21-questions scale has 3 subscales 
(each contains 7 items) measuring depression, anxiety and stress, respectively. All items are 
scored on a zero to 3. Since DAS-21 is the short version of DAS-42; thus, the final score of 
each subclass must to be doubled. Higher score presenting more severe negative symptoms. 
The valid and reliable Persian revision of DASS-21 scale was used in this survey [36]. 
The Insomnia Severity Index (ISI) is a reliable tool which quantitatively measures a severity 
of insomnia [37]. The questionnaire involves 7 questions dealing on sleep disorder intensity, 
sleep-associated satisfaction and anxiety-associated sleeping disorder. Each items are rated 
from zero to 4 to provide a total score ranging 0- 28. Higher scores point out more degree of 
insomnia.  
The Epworth Sleepiness Scale (ESS) is an accepted and validated questionnaire which can be 
used to measure daytime sleepiness. It have eight items with 4-point Likert scale (0-3) which 
quantifies the frequent probability of fall asleep in most common daily living conditions. 
Total scores range from 0-24 and higher scores indicate worsen sleepiness [38]. 
The Short Form health survey (SF-12) is a widely accepted tool for measuring health-related 
quality of life [39]. The generic instrument is a shorter version of the SF-36, and composed of 
12 questions creates normalized physical and mental health subscales included in the SF-36. 
The Iranian version of the SF-12 revealed good psychometrically reliability and validity [40]. 
Personality Type A/B Inventory developed by Rathus has 25 items questionnaire and 
individuals concerning to their mood and states have to response: yes (score=1) or no 
(score=0) [41]. Type A personality describes a complex emotional individual who often have 
an aggressive mood, active, opponent, competitive, chivalrous and having different standards 
and activities. While, type B personality has features such as feeling less pressure, having 
regular rest/exercise, lower standard and slow working [42, 43]. This instrument divides 
individual personality types into two classes: type A (> score 13) and type B (<13). The 
validity and reliability of this instrument was confirmed for Iranian population[41, 44].  
2.5. Statistical analysis 
Statistical analyses were conducted by using the SPSS for Windows version 16.0 (Statistical 
Package for Social Sciences Inc., Chicago, USA). Continuous variables are presented as 
mean ± SD and were compared between groups using independent sample T-test. Categorical 
variables presented as number (percent) and compare between groups by Chi-square test. The 
correlation between PSST score and neuropsychological tests was evaluated using Pearson 
correlation analysis. Univariate linear regression analysis was used to assess the effects of 
PSST scores on neuropsychological performances. A p value <0.05 was considered to be 
statistically significant. 
3. Results 
Of the 182 young females in the population sample, 31(17.0%) were found to have IBS. IBS 
subtypes included IBS-D 12.9%, IBS-C 9.7%, IBS-M 64.7%, and unsubtyped IBS 9.7%. The 
most predominant symptoms of IBS were alterations in bowel frequency (96.8%), alterations 
in fecal consistency (90.3%), and abdominal pain which was alleviated by defecation 
(61.3%). Constipation was present in 41.9% of IBS subjects, diarrhea was found in 25.8%, 
and 22.6% presented with intermittent diarrhea and constipation. The clinical features of the 
participants are summarized in Table 1. No significant difference was found between IBS and 
Non-IBS groups in terms of age, BMI, SBP, DBP, waist: hip ratio and hematological indices 
(Table 1). 
The distribution of menstrual pattern and common physiological symptoms of PMS between 
two groups are presented in Table 2. Average days of bleeding was significantly greater in 
the IBS group compared to non-IBS group (p=0.002). Also, in the non-IBS group, the mean 
pain severity of PSST scale was significantly lower than that in IBS groups (P=0.001). 
Among physiological symptoms of PMS, prevalence of muscular pain is statistically 
significant higher in group with IBS compared to No IBS group (p=0.049). 
3.1.Neuropsychological function in relation to IBS 
The women with IBS did not perform worse than the non-IBS group for all of the cognitive 
abilities tasks (P>0.05). But, the non-IBS individuals scored more favorably than the women 
with IBS in the Dass-21 test (depressed mood), insomnia intensity, severity of daytime 
sleepiness, and nocturnal sleeping (P<0.05; Table 3). Personality type of 48.4% of IBS cases 
were type A, whereas 36.4% of No-IBS group had type A personality, the difference was not 
statistically significant (P=0.16) 
3.2.Neuropsychological function in relation to PMS 
The correlation between the PSST score and cognitive abilities, depression, anxiety, stress, 
quality of life, insomnia and daytime sleepiness scores using Pearson correlation analysis are 
shown in Table 4. The PSST score was significantly correlated with scores for depression 
(r=0.29; p<0.001), anxiety (r=0.28; p<0.001), stress (r=0.32; p<0.001), insomnia (r=0.34; 
p<0.001) and daytime sleepiness (r=0.31; p<0.001); while they were negatively correlated 
with cognitive abilities (r=-0.20; p=0.006) and quality of life(r=-0.42; p<0.001). 
Univariate linear regression analysis was conducted to evaluate the association of PSST score 
and neuropsychological test scores in two IBS and No-IBS groups (Table 5). PSST score 
appeared to be a significant factor in determining the scores of depression, anxiety, stress, 
quality of life, insomnia and daytime sleepiness in both groups (P<0.05). 
4. Discussion 
To best of our knowledge, this work is the first study to show women who report IBS in 
addition to PD and PMS have a significantly higher PSST score, the average days of bleeding 
and frequency of some physical symptoms of PMS compared to those without it. They also 
more suffer from more degree of some neuropsychological problems including depression, 
insomnia, daytime sleepiness compared to IBS-cases. In contrast to the previous studies we 
have compared a group of affected patients (both PD and PMS) with women affected by both 
PD and PMS, and not with a healthy control group. 
Identifying the co-occurrence of one or more physical or psychological complications is 
important. The reason is that this comorbidity can lead to difficulty in making a correct 
diagnosis because of the confounding manifestations of a patient's main problem; it can also 
affect the correct interpretation of research results, and causes worse health outcomes 
compared to the presence of a single problem. 
Previous studies have indicated that PD and PMS co-occur in 25–50% of women with IBS 
[25, 45]. One the other hand, in one population-based, postal study, 26% of women with PD 
had IBS according to Rome III after 10 years follow-up [46]. In addition, female with IBS 
experience higher sensitivity to rectal distention than female without it, especially during 
menstruation [16], proposing elevated visceral sensitivity within the period of reducing 
ovarian hormone amounts [47]. Regarding the somatic, psychological and gastrointestinal 
symptoms across the menstrual cycle, individuals with IBS had serious manifestations 
compared to healthy controls [25]. Altman and co-workers reported that the presence of PMS 
alone or PMS plus PD in IBS patients is associated with an exacerbation of symptoms 
reported during the luteal and the menses phases [48]. This suggests that the symptoms of 
IBS are aggravated during menses and cyclical alterations in rectal sensitivity is closely 
related to differently response to fluctuations in sex hormonal environment [16]. Therefore, it 
is crucial to account for concomitant other conditions that may influence symptom intensity 
and menstrual cycle phase in assessing treatment response. For example, the treatment of 
PMS woman with antidepressants which have anticholinergic features may further worsen 
symptoms in women with IBS-C. 
Altogether, a total 16 tests of cognitive abilities, emotional/behavioral factors, sleep pattern 
and personality were administered to the study population. For four of these tests including 
depressed mood, insomnia, daytime sleepiness, and nocturnal sleep, the Non-IBS participants 
scored significantly more favorably compared to those with IBS. It has been shown that 
personality and affective characteristics are main elements of the IBS biopsychosocial model, 
being contributed in performance and dysregulation of the brain-gut connection, and 
involving to the formation, recurrence and relapse of IBS[49]. 
It has been reported that an increased level of neuroticism, conscientiousness, lie score, 
psychoticism, openness while decreased values of extraversion and crime in IBS-patients 
compared to healthy control [50, 51]. In a study among adolescents from Sri Lanka, IBS 
cases demonstrated higher hostility and aggression, negative self-esteem and self-adequacy, 
emotional unresponsiveness and instability as well as negative world view versus normal 
cases [52]. In Korean IBS patients, anxiety and depression trait that was evaluated using the 
Hospital Anxiety and Depression Scale (HADS) closely associated with the degree of IBS-
related symptoms [53]. In longitudinal study among Taiwanese population, IBS patients had 
2.7- and 2.4-times greater risk of developing depression and sleep complication, respectively, 
than healthy controls [54], indicating IBS as a causal risk factor for psychiatric disorders.  
Patients with IBS are more vulnerable to stressful experiences, which generate 
gastrointestinal manifestations [55]. Psychiatric complications are linked with variations in 
the formation of visceral sensations in IBS patients, which could explain the symptoms of 
IBS [56]. In accordance with our results, the prevalence of insomnia and sleepiness in 
patients with IBS was greater than healthy individuals in previous reports [57-59]. 
. 
Insomnia is found in up to 20% of adults and is characterized by difficult falling asleep, 
maintenance of sleep, early morning awaking, poor sleep quality and lower satisfaction with 
sleep pattern [60]. A recent meta-analysis of published data claimed that sleep impairment 
were found in 37.6% of IBS was patients [61]. Interestingly, in a recent survey, the 
coexistence of both depression and insomnia is remarkably associated with higher risk of 
developing IBS in comparison with to each individual occurrence [62]. Balikji et al reported 
that IBS symptom severity was significantly correlated with insomnia, sleep quality, sleep 
onset latency as well as the frequency of night awakening  [63]. 
The brain–gut connection contributed in the pathogenesis of IBS. Sleep disturbance cause to 
altering the activation of the autonomic nervous system implicating that sleep problems may 
be related with autonomic dysregulation [64, 65]. Moreover, IBS complaints, particularly 
pain, frequently have an adverse effect on sleep. One the other hand, sleep has a critical role 
in the immune system, and insufficient or sleep difficulty could induce immune dysfunction, 
which could lead in the inflammatory mucosal alterations observed in IBS cases [66, 67]. 
Thus, the relationship of IBS and insomnia is of a reciprocal nature. Deprivation or 
insufficient sleep for any reason promotes pain. These evidences propose that the 
improvement of sleep will decrease IBS-related pain.  
As we have found, results from several observational studies did not support the casual 
association between IBS disease process and cognitive impairments. IBS patients were not 
different from healthy controls regarding the executive function, absolute IQ and recognition 
scores, Spatial Working Memory tests, psychomotor speed, attention and interference tests, 
intelligence tests [68-70].  
The question that arises is whether the severity of IBS aggravates the patients’ anxiety 
depression and sleep problems or do their anxiety, depression and sleep problems exaggerate 
their IBS severity? Since this was a cross-sectional survey and not a longitudinal design, it is 
not possible to establish causal relationships. It is obvious that PMS symptoms and 
anxiety/depression or sleep problems have bidirectional and feedback impacts on each other. 
Nevertheless, there are several limitations to this study. Due to its cross-sectional design of 
study, we were not able to determine cause and effect associations. The subjects with IBS in 
current work were not sub-grouped to those with IBS-C, IBS-D, or IBS-M because of the 
small sample size each subtype. Thus, further investigations are also needed to study IBS 
population in detail and described whether menstrual patterns and associated symptoms differ 
between IBS subtypes. 
Conclusion: 
IBS may be related to several psychiatric comorbidities, in particular depression, sleep 
problems and menstrual-associated disorders. In particular, IBS can exacerbate PMS 
symptoms. Another implication of the current study is the close relationship between 
cognitive dysfunction, depression, anxiety, sleep disturbance and PMS symptom severity.  It 
is most likely that the severity of gastrointestinal symptoms and psychological distress 
collectively cause the increased reporting of severe PMS symptoms in women. So, in PMS 
management, it is important to increase awareness among clinicians and gynecologists 
concerning to the relationships between PMS and IBS.  
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P value * 
Age (years) 20.7±1.7 20.4±4.0 0.48 
BMI (kg/m2) 20.9±2.9 20.3±2.8 0.32 
SBP(mmHg) 10.6±0.96 10.8±0.99 0.44 
DBP(mmHg) 7.1±0.75 7.4±0.77 0.56 
WHR 0.73±0.04 0.74±0.03 0.46 
Hematological indices 
WBC (109 cells/L) 6.8±1.8 7.1±1.9 0.46 
RBC(1012 cells/L) 4.8±0.5 4.8±0.4 0.89 
HCT (%) 41.6±3.6 41.1±3.3 0.46 
Hb (g/dL) 13.9±1.4 13.8±1.6 0.67 
BMI: body mass index; Hb: hemoglobin; HCT: hematocrit; IBS: irritable bowel syndrome; SBP: systolic 
blood pressure; DBP: diastolic blood pressure; WHR: waist: hip ratio. 
Data presented as mean±SD 




Table 2. Relationship between menstrual pattern, PSST score and physiological symptoms with 





P value * 
Age of menstruation, years 13.1±1.4 13.1±1.2 0.77 
Average days of bleeding 6.5±1.1 7.8±4.1 0.002 
Duration of the menstruation 
cycle (day) 
28.0±3.9 27.4±5.4 0.52 
PSST sore 32.2±9.8 38.7±9.7 0.001 
Dysmenorrhea pain score 7.2±2.1 7.3±2.6 0.92 
Menstruation-associated physical symptoms, n(%) 
Tender breasts 94(62.3) 22(71) 0.36 
Backache 142(94.0) 31(100) 0.16 
feeling of bloating 142(94.0) 30(96.8) 0.54 
Weight gain 69(45.7) 17(54.8) 0.35 
Swelling of the limbs 78(51.7) 22(71.0) 0.049 
joint or muscle pain 129(85.4) 30(96.8) 0.83 
Gastrointestinal symptoms 122(80.8) 27(87.1) 0.40 
Use of medicine for relieving 
pain 
82(54.3) 15(48.4) 0.66 
Data presented as mean±SD or number (%). 
*By using independent sample T test or chi-square test as appropriate. 
 
  
Table 3. Association of cognitive ability, emotional performance, personality and sleep pattern with 
presence of IBS. 




P value * 
Test of cognitive abilities 
Memory 25.6±3.1 24.5±4.5 0.08 
Inhibitory control and selective 
attention 
22.0±3.8 21.4±4.6 0.45 
Decision making 19.0±3.7 18.2±3.7 0.28 
Planning 11.1±2.8 10.5±3.0 0.26 
Sustain attention 9.6±2.4 8.7±2.4 0.06 
Social cognition 10.6±2.1 11.2±2.0 0.16 
Cognitive flexibility 14.6±2.8 14.1±2.8 0.35 
Total cognitive ability task 112.6±14.0 108.6±14.8 0.15 
Dass-21 
Depression 10.5±8.6 14.0±10.2 0.046 
Anxiety 8.5±6.0 10.7±7.4 0.078 
Stress 17.0±9.6 19.3±11.4 0.26 
Quality of life (SF-12) 
Physical health  15.9±2.4 15.3±3.0 0.25 
Mental health  16.5±3.6 15.7±4.2 0.24 
Total Quality of life score  32.4±5.0 31.5±5.7 0.36 
Test of sleep pattern 
Insomnia score (ISI) 5.7±6.4 8.7±8.3 0.025 
Daytime sleepiness score (ESS) 5.8±5.7 8.9±6.2 0.008 
Nocturnal sleep hours 7.4±1.3 6.7±1.5 0.008 
Personality 
Type A 55(36.4) 15(48.4) 
0.16 
Type B 96(63.6) 16(51.6) 
Data presented as mean±SD or number (%). 
*Obtained from independent sample T-test or chi-square tests as appropriate. 
 
  
Table 4. Correlation matrix between PSST score and neuropsychological tests in subjects 











r 0.29 -0.50  
p <0.001 <0.001 Depression  
Anxiety 
r 0.28 -0.46 0.57 
p <0.001 <0.001 <0.001 Anxiety  
Stress 
r 0.32 -0.52 0.57 0.61 
p <0.001 <0.001 <0.001 <0.001 Stress 
Quality of life 
r -0.42 0.36 -0.48 -0.44 -0.51 
p <0.001 <0.001 <0.001 <0.001 <0.001 Quality of 
life 
Insomnia 
r 0.34 -0.12 0.22 0.33 0.24 -0.41 
p <0.001 0.11 0.003 <0.001 0.001 <0.001 Insomnia 
Daytime 
sleepiness 
r 0.31 -0.32 0.30 0.37 0.23 -0.32 0.52 
p <0.001 <0.001 <0.001 <0.001 0.002 <0.001 <0.001 
 
  
Table 5. Linear regression analysis the effect of PSST score on cognitive abilities, 
depression, anxiety, stress, quality of life, insomnia and daytime sleepiness scores as the 
dependent variables across IBS categories. 
Variables No-IBS IBS 
Β  P value Β P value 
Cognitive abilities -0.21 0.07 -0.53 0.05 
Depression 0.20 0.004 0.41 0.032 
Anxiety 0.12 0.014 0.36 0.008 
Stress 0.25 0.002 0.62 0.002 
Quality of life -0.18 <0.001 -0.44 <0.001 
Insomnia 0.16 0.002 0.50 0.001 
Daytime sleepiness 0.14 0.003 0.29 0.010 
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